Generic placeholder image

Current Pharmaceutical Design

Author(s): Amit Alexander*, Mukta Agrawal, Swarnlata Saraf, Shailendra Saraf, Ajazuddin and Mahavir B. Chougule*

DOI: 10.2174/1381612826666200212120947

DownloadDownload PDF Flyer Cite As
Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs

Page: [3269 - 3280] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

NLC is a next-generation lipid nanocarrier, which holds many advantages over other colloidal lipid carrier systems like higher drug loading, better and controlled release and enhanced stability. Owing to the unique structural composition, i.e. crystallized solid and liquid lipid blend, it offers excellent biocompatibility and higher permeation across physiological membranes like BBB. Moreover, the surface of NLC can easily be modified with target-specific ligands, proteins, peptides, etc. which makes it a potential candidate for brain targeting of CNS acting drugs. NLC has found various applications for the treatment of various CNS disorders including Alzheimer’s disease, Parkinson’s disease, schizophrenia, epilepsy, migraine, cerebral ischemia, etc. Among these, the application of NLC towards the treatment of AD has been well-explored in the past two decades. In this piece of work, we have discussed the types of NLC, its composition, fabrication techniques, characterization, stability profile and application in the treatment of AD.

Keywords: Nanostructured lipid carrier, lipid, brain, BBB, Alzheimer's disease, fabrication techniques.

[1]
Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett 2013; 334(2): 157-75..
[http://dx.doi.org/10.1016/j.canlet.2012.07.006 ] [PMID: 22796606]
[2]
Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018; 281: 139-77.
[http://dx.doi.org/10.1016/j.jconrel.2018.05.011] [PMID: 29772289]
[3]
Miao J, Du YZ, Yuan H, Zhang XG, Hu FQ. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces 2013; 110: 74-80.
[http://dx.doi.org/10.1016/j.colsurfb.2013.03.037] [PMID: 23711779]
[4]
Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2014; 117: 21-8.
[http://dx.doi.org/10.1016/j.colsurfb.2014.01.055] [PMID: 24607519]
[5]
Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008; 70(2): 633-40.
[6]
Agrawal M, Ajaz uddin, Tripathi DK, Saraf S, Antimisiaris SG, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. Journal of controlled release : official journal of the Controlled Release Society 2017; 260: 61-77.
[7]
Alexander A, Saraf S, Saraf S, Agrawal M, Patel RJ, Agrawal P, et al. Amalgamation of stem cells with nanotechnology: A unique therapeutic approach. Curr Stem Cell Res Ther 2018.
[PMID: 29968543]
[8]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. Journal of controlled release : official journal of the Controlled Release Society 2017; 264: 306-2..
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033]
[9]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[10]
Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. J Drug Target 2014; 22(7): 576-83.
[http://dx.doi.org/10.3109/1061186X.2014.934688] [PMID: 25012065]
[11]
Simoes S, Figueiras A, Veiga F, Concheiro A. alvarez-lorenzo C. Polymeric micelles for oral drug administration enabling locoregional and systemic treatments. Expert Opin Drug Deliv 2014; 12: 1-22.
[12]
Pund S, Joshi A. Chapter 23 - Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art. In: Grumezescu AM, Ed. Nano- and Microscale Drug Delivery Systems.Elsevier 2017; pp. 439-80.
[13]
Arms L, Smith DW, Flynn J, et al. Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles. Front Pharmacol 2018; 9(802): 802.
[http://dx.doi.org/10.3389/fphar.2018.00802] [PMID: 30154715]
[14]
Tsai H-C, Imae T. Fabrication of Dendrimers Toward Biological Application.Villaverde A, Ed Progress in Molecular Biology and Translational Science 104 Academic Press. 2011; pp. 101-40..
[15]
Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 2014; 6(3): 139-50.
[http://dx.doi.org/10.4103/0975-7406.130965] [PMID: 25035633]
[16]
Chandran PR, Thomas RT. Gold Nanoparticles in Cancer Drug Delivery. In: Thomas S, Grohens Y, Ninan N, EdsNanotechnology Applications for Tissue Engineering. Oxford: William Andrew Publishing 2015; pp. 221-37.
[http://dx.doi.org/10.1016/B978-0-323-32889-0.00014-5]
[17]
Matea CT, Mocan T, Tabaran F, et al. Quantum dots in imaging, drug delivery and sensor applications. Int J Nanomedicine 2017; 12: 5421-31.
[http://dx.doi.org/10.2147/IJN.S138624] [PMID: 28814860]
[18]
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol 2015; 6: 286..
[http://dx.doi.org/10.3389/fphar.2015.00286] [PMID: 26648870]
[19]
Kazi KM, Mandal AS, Biswas N, et al. Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res 2010; 1(4): 374-80.
[http://dx.doi.org/10.4103/0110-5558.76435] [PMID: 22247876]
[20]
Esim O, Kurbanoglu S, Savaser A, Ozkan SA, Ozkan Y. Chapter 9- Nanomaterials for Drug Delivery Systems In: Ozkan SA, Shah A, Eds. New Developments in Nanosensors for Pharmaceutical Analysis.Academic Press 2019; pp. 273-301.
[21]
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71(4): 349-58.
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[22]
Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[23]
Fang C, Al-Suwayeh S, Fang J-Y. Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Recent Pat Nanotechnol 2012.. In press
[http://dx.doi.org/10.2174/1872210511307010041] [PMID: 22946628]
[24]
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1): 102.
[http://dx.doi.org/10.1186/1556-276X-8-102] [PMID: 23432972]
[25]
Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009; 26(6): 523-80.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10] [PMID: 20402623]
[26]
Abdelkader H, Alani AW, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2014; 21(2): 87-100.
[http://dx.doi.org/10.3109/10717544.2013.838077] [PMID: 24156390]
[27]
Callender SP, Mathews JA, Kobernyk K, Wettig SD. Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery. Int J Pharm 2017; 526(1-2): 425-42.
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.005] [PMID: 28495500]
[28]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45(1): 89-121.
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[29]
Agrawal M, Alexander A, Khan J, et al. Recent Biomedical Applications on Stem Cell Therapy: A Brief Overview. Curr Stem Cell Res Ther 2019; 14(2): 127-36.
[http://dx.doi.org/10.2174/1574888X13666181002161700] [PMID: 30280676]
[30]
Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv 2016; 13(8): 1121-31.
[http://dx.doi.org/10.1080/17425247.2016.1178237] [PMID: 27073977]
[31]
Weber S, Zimmer A, Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art 2014; 86(1): 7-22.
[32]
Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 2007; 2(4): 595-607.
[PMID: 18203427]
[33]
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12(1): 62-76..
[http://dx.doi.org//10.1208/s12249-010-9563-0] [PMID: 21174180]
[34]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[35]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 103: 598-613..
[http://dx.doi.org/10.1016/j.biopha.2018.04.055]
[36]
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 2017; 9(2) E12
[http://dx.doi.org/10.3390/pharmaceutics9020012]] [PMID: 28346375]
[37]
Costa C, Brandão F, Bessa MJ, et al. In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests. J Appl Toxicol 2016; 36(3): 361-72.
[http://dx.doi.org/10.1002/jat.3213] [PMID: 26212026]
[38]
Aditya NP, Shim M, Lee I, Lee Y, Im MH, Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J Agric Food Chem 2013; 61(8): 1878-83.
[http://dx.doi.org/10.1021/jf305143k] [PMID: 23362941]
[39]
Alexander A, Sharma S, Ajaz A, Khan J. Swarna. Theories and Factors affecting Mucoadhesive Drug Delivery Systems: A Review Int J Res Ayurveyda Pharm 2011; 2(4): 1155- 61.
[40]
Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88(24): 11460-4.
[http://dx.doi.org/10.1073/pnas.88.24.11460] [PMID: 1763060]
[41]
Woodle MC. Sterically stabilized liposome therapeutics. Adv Drug Deliv Rev 1995; 16(2): 249-65.
[http://dx.doi.org/10.1016/0169-409X(95)00028-6]
[42]
Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009; 86(3): 215-23.
[http://dx.doi.org/10.1016/j.yexmp.2008.12.004] [PMID: 19186176]
[43]
Severino P, Santana MHA, Souto EB. Optimizing SLN and NLC by 2(2) full factorial design: effect of homogenization technique. Mater Sci Eng C 2012; 32(6): 1375-9.
[http://dx.doi.org/10.1016/j.msec.2012.04.017] [PMID: 24364934]
[44]
Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23(4): 377-88.
[http://dx.doi.org/10.1080/02652040500435295] [PMID: 16854814]
[45]
Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010; 394(1-2): 179-85.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[46]
Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008; 346(1-2): 124-32.
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.060] [PMID: 17651933]
[47]
Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 2002; 239(1-2): 121-8.
[http://dx.doi.org/10.1016/S0378-5173(02)00081-9] [PMID: 12052697]
[48]
Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22(5): 501-10..
[http://dx.doi.org/10.1080/02652040500162436] [PMID: 16361193]
[49]
Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011; 19(1): 23-32.
[PMID: 22615636]
[50]
Liu D, Ge Y, Tang Y, et al. Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies. J Microencapsul 2010; 27(8): 726-34.
[http://dx.doi.org/10.3109/02652048.2010.513456] [PMID: 21034365]
[51]
Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005; 45(3-4): 167-73.
[http://dx.doi.org/10.1016/j.colsurfb.2005.08.005] [PMID: 16198092]
[52]
Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm 2013; 454(1): 573-83.
[http://dx.doi.org/10.1016/j.ijpharm.2013.03.034] [PMID: 23535345]
[53]
Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. Journal of controlled release : official journal of the Controlled Release Society 2005; 108(1): 112-20..
[http://dx.doi.org/10.1016/j.jconrel.2005.07.023]
[54]
Abdel-Mottaleb MM, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm 2011; 79(1): 36-42.
[http://dx.doi.org/10.1016/j.ejpb.2011.04.009]
[55]
Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces 2014; 113: 15-24.
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.032] [PMID: 24060926]
[56]
Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012; 9(5): 497-508.
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[57]
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3): 165-96.
[http://dx.doi.org/10.1016/S0169-409X(01)00105-3] [PMID: 11311991]
[58]
Alexander A, Ajaz A, Swarna Sharma M, Tripathi DK. Polymers and Permeation Enhancers: Specialized Components of Mucoadhesives. Stamford J Pharm Sci 2011; 4(1): 91-5.
[59]
Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018; 13(4): 288-303.
[http://dx.doi.org/10.4103/1735-5362.235156] [PMID: 30065762]
[60]
Alexander A. Ajazuddin, Khan J, Saraf S, Saraf S. Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate. J Pharm Pharmacol 2014; 66(9): 1240-50.
[http://dx.doi.org/10.1111/jphp.12262] [PMID: 24824413]
[61]
Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol 2013; 19: 29-43.
[http://dx.doi.org/10.1016/j.ifset.2013.03.002]
[62]
Zattoni A, Roda B, Borghi F, Marassi V, Reschiglian P. Flow field-flow fractionation for the analysis of nanoparticles used in drug delivery. J Pharm Biomed Anal 2014; 87: 53-61.
[http://dx.doi.org/10.1016/j.jpba.2013.08.018] [PMID: 24012480]
[63]
Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. nvestigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy Journal of controlled release : official journal of the Controlled Release Society 2004; 95(2): 217-7..
[64]
Xu R. Progress in nanoparticles characterization: Sizing and zeta potential measurement. Particuology 2008; 6: 112-5.
[http://dx.doi.org/10.1016/j.partic.2007.12.002]
[65]
Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012; 52: 481-503.
[http://dx.doi.org/10.1146/annurev-pharmtox-010611-134623] [PMID: 22035254]
[66]
Truong NP, Whittaker MR, Mak CW, Davis TP. The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Deliv 2015; 12(1): 129-42.
[http://dx.doi.org/10.1517/17425247.2014.950564] [PMID: 25138827]
[67]
Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res 2005; 22(11): 1887-97..
[http://dx.doi.org/10.1007/s11095-005-7148-5] [PMID: 16132349]
[68]
Teeranachaideekul V, Souto EB, Junyaprasert VB, Muller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 2007; 67(1): 141-8.
[69]
Barbosa JP, Neves AR, Silva AM, Barbosa MA, Reis MS, Santos SG. Nanostructured lipid carriers loaded with resveratrol modulate human dendritic cells. Int J Nanomedicine 2016; 11: 3501-16.
[http://dx.doi.org/10.2147/IJN.S108694] [PMID: 27555771]
[70]
Klang V, Valenta C, Matsko NB. Electron microscopy of pharmaceutical systems. Micron (Oxford, England : 1993). 2013; 44: 45-74.
[http://dx.doi.org/10.1016/j.micron.2012.07.008]
[71]
Khan S, Shaharyar M, Fazil M, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization. Eur J Pharm Biopharm 2016; 108: 277-88.
[72]
Pardeike J, Weber S, Matsko N, Zimmer A. Formation of a physical stable delivery system by simply autoclaving nanostructured lipid carriers (NLC). Int J Pharm 2012; 439(1-2): 22-7.
[http://dx.doi.org/10.1016/j.ijpharm.2012.09.018] [PMID: 22989983]
[73]
Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 2006; 314(1): 56-62.
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.022] [PMID: 16574354]
[74]
Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 2014; 477(1-2): 519-26.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067] [PMID: 25445970]
[75]
Esposito E, Ravani L, Drechsler M, et al. Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study. Mater Sci Eng C 2015; 48: 328-36.
[http://dx.doi.org/10.1016/j.msec.2014.12.012] [PMID: 25579930]
[76]
Cortesi R, Valacchi G, Muresan XM, et al. Nanostructured lipid carriers (NLC) for the delivery of natural molecules with antimicrobial activity: production, characterisation and in vitro studies. J Microencapsul 2017; 34(1): 63-72.
[http://dx.doi.org/10.1080/02652048.2017.1284276] [PMID: 28097914]
[77]
Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine (Lond) 2016; 12(1): 143-61..
[http://dx.doi.org//10.1016/j.nano.2015.09.004] [PMID: 26410277]
[78]
Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 2007; 59(6): 379-402.
[http://dx.doi.org/10.1016/j.addr.2007.04.013] [PMID: 17658653]
[79]
Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012; 11: 159.
[http://dx.doi.org/10.1186/1476-511X-11-159] [PMID: 23167765]
[80]
Varshosaz J, Eskandari S, Tabakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol 2010; 15(1): 89-96.
[http://dx.doi.org/10.3109/10837450903013568] [PMID: 19552542]
[81]
Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 2014; 116: 81-7.
[http://dx.doi.org/10.1016/j.colsurfb.2013.12.012] [PMID: 24445002]
[82]
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Controlled Soc 2018; 281: 139-77.
[83]
Anand A, Patience AA, Sharma N, Khurana N. The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review. Eur J Pharmacol 2017; 815: 364-75.
[http://dx.doi.org/10.1016/j.ejphar.2017.09.043] [PMID: 28978455]
[84]
Kumar P, Sharma G, Kumar R, et al. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: Biochemical, pharmacokinetic and biodistribution evidences. Int J Pharm 2016; 515(1-2): 307-14.
[http://dx.doi.org/10.1016/j.ijpharm.2016.10.024] [PMID: 27756627]
[85]
Li W, Zhou M, Xu N, et al. Comparative analysis of protective effects of curcumin, curcumin-β-cyclodextrin nanoparticle and nanoliposomal curcumin on unsymmetrical dimethyl hydrazine poisoning in mice. Bioengineered 2016; 7(5): 334-41.
[http://dx.doi.org/10.1080/21655979.2016.1197029] [PMID: 27710431]
[86]
Meng F, Asghar S, Xu Y, et al. Design and evaluation of lipoprotein resembling curcumin-encapsulated protein-free nanostructured lipid carrier for brain targeting. Int J Pharm 2016; 506(1-2): 46-56.
[http://dx.doi.org/10.1016/j.ijpharm.2016.04.033] [PMID: 27094357]